Affordable Access

CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease.

Authors
Type
Published Article
Journal
Seminars in Oncology
0093-7754
Publisher
Elsevier - WB Saunders
Publication Date
Volume
13
Issue
1 Suppl 1
Pages
23–26
Identifiers
PMID: 2420012
Source
Medline

Abstract

Starting in February 1980, 58 patients with Hodgkin's disease refractory to both MOPP and ABVD received as third-line chemotherapy a combination of CCNU or lomustine, etoposide, and prednimustine (CEP). Complete response (CR) was achieved in 40% of cases and partial response (PR) in 14%. The median duration of CR was greater than 15 months, and the median survival of complete responders was longer than 24 months. In addition, CEP alternating with ABVD was given to 21 patients refractory to MOPP chemotherapy. In this series, CR was documented in 67% of patients with a median duration of 24+ months and a median survival of 36+ months. Treatment was generally well tolerated, and all acute side effects were reversible. Present findings indicate that CEP is an effective regimen in patients refractory to MOPP and ABVD.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments